PharmaCyte Biotech, Inc. Appoints José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer
August 10, 2020 at 06:30 pm IST
Share
PharmaCyte Biotech, Inc. announced that it has appointed José L. Iglesias M.D. as Consulting Chief Medical Officer (CMO) for its planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). Dr. Iglesias brings a wealth of experience in developing and testing a variety of cancer chemotherapeutic agents to PharmaCyte, including key positions with many prominent biotechnology firms including Eli Lilly, Amgen, Abraxis and Celgene. Dr. Iglesias’s body of work is ideally suited to guide PharmaCyte through its planned Phase 2b clinical trial in LAPC. As the global Vice-President of Clinical Development at Celgene, Dr. Iglesias was the lead physician on the team that obtained FDA approval for Abraxane® (the nab-paclitaxel/gemcitabine combination), which is a first-line therapy in pancreatic cancer. Dr. Iglesias is also familiar and experienced with the treatment of various abdominal cancers and the use of gemcitabine in patients. He was instrumental in the design of the Phase 3 clinical trial for the development of nab-paclitaxel for use against metastatic pancreatic cancer while at Celgene.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.